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In this mini review, we would like to challenge the well-
established ‘fact’ that lead exposure causes chronic renal
failure (CRF). Even though only scarce evidence exists of the
relationship between lead and renal failure, a World Health
Organization Environmental Health Criteria document
summarizes that ‘Lead has been a very common cause of
acute or chronic renal failure’. It is also written and cited in
textbooks and numerous publications that chronic lead
nephropathy causes a slowly progressive interstitial nephritis
manifested by a reduced glomerular filtration rate, and that
there is a growing consensus that lead contributes to
hypertension in the general population. We will argue that,
when published reports are carefully scrutinized, such
statements on lead and CRF are not evidence based but are
rather founded on a few narrative reports on lead-exposed
individuals and statistical associations between lead and
serum creatinine (or urea) in a few population studies.
We will, however, not argue that lead is not toxic and that
lead does not cause other types of severe health effects
where the evidence is unquestionable, but we do not believe
that the kidneys are an early victim after lead exposure.
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Lead toxicity has affected human civilization for thousands of
years. It has even been proposed that lead poisoning (caused
by lead–laden water pipes) contributed to the fall of the
Roman Empire.1 Patients suffering from overt lead poisoning
(seen at blood lead levels (PbB) 480 mg/dl) have symptoms
of anemia, colic pain, peripheral neuropathy, and encepha-
lopathy. It has been claimed and stated throughout the
twenty-first century that lead exposure may also cause lead
nephropathy and chronic renal failure (CRF).2–4 During the
recent decades, several epidemiological studies have pre-
sented suggestive evidence that low levels of environmental
lead cause kidney disease in large proportions of the general
population.5,6 It has also been suggested that low levels
of environmental lead exposure contributes to increased
cardiovascular mortality7,8 and high blood pressure,9,10 and
that these effects are mediated through kidney disease.11 In
this narrative mini review, we challenge the epidemiological
and pathophysiological evidence of lead exposure as a risk
factor for the development of CRF. The extent of this
minireview prevents us from an in-depth discussion on lead
exposure as a cause of hypertension and cardiovascular
mortality. We searched in PubMed using the words ‘lead’,
‘nephrotoxicity’, ‘epidemiologic’, ‘experimental’, ‘kidney dis-
ease, chronic’, and ‘renal’ to find all original articles and
reviews of relevance to our topic that are written in English.
In addition, we used other sources available to us by
‘snowballing’, cross-references in previous articles, and books
read by the authors.
HUMAN EXPOSURE AND ACCUMULATION OF LEAD
Lead enters the human body by ingestion or inhalation.
Children are especially vulnerable to lead exposure; they
experience toxic effects at lower limits, and also have higher
gastrointestinal absorption compared with adults.12 Ambient
air exposure to lead has decreased during the past decades
mainly because of legislative actions aiming at removing lead
in petrol.13 Data from the National Health and Nutrition
Examination Survey study in the United States show a decline
in the geometric mean PbB level in the general population
from 13.1 mg/dl in 1976–1988 to 1.6 mg/dl in 1999–2002.14
Factors that have been linked to higher PbB are older age,
male sex, lead in old paint and water pipes, smoking,
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moonshine drinking, lower socioeconomic status, urban
residence, and housing in older buildings.2,7,14,15
The absorbed lead is accumulated in the body in three
compartments. The PbB rises fast after lead exposure, but
soon lead is redistributed to soft tissues and bones.16 About
95% of the absorbed lead is stored in the bones of adults,
o5% of the PbB is free in the plasma, and the rest is bound
to the erythrocytes. Within the erythrocyte lead is bound to
the enzyme d-aminolevulinic acid (ALAD). The biologic half-
life differs between the three compartments. The half-life in
blood and soft tissues is about 30 days, whereas the half-life
in the bones is 4–20 years; lead in trabecular bone has a much
shorter half-life than lead in cortical bone.17–19
BIOMARKERS OF LEAD EXPOSURE
Because of the short mean biological life in blood, PbB
primarily reflects on-going exposure. However, if exposure to
lead has been going on for a long period of time, giving rise
to a high body burden of lead, PbB will remain elevated for
an extended period of time.20 To measure the accumulated
lead (lead burden), one can perform a mobilization test using
a chelating agent. This is carried out by intramuscular or
intravenous administration of CaNa2 EDTA. Oral dimercap-
tosuccinic acid is another option. Lead has higher affinity to
EDTA than calcium, and the lead–EDTA complex is excreted
and can be measured in the urine during the following 24 h.
The administration of EDTA is used both as a diagnostic test
of the stored body lead burden and repeatedly to treat lead
intoxication (4600 mg excreted lead/24 h).21,22 A non-
invasive way to measure stored lead is by in vivo X-ray
fluorescence. PbB and the EDTA test are correlated under
steady-state circumstances,16,23 especially if the exposure is
recent.16 This is probably because most of the chelatable lead
comes from the blood–soft tissue compartments, and to a
lesser extent from trabecular (calcaneus) bone with higher
bioavailability compared with cortical bone (tibia).17 The
clinical importance of the stored lead is not clear, but it has
been suggested that it may contribute to general toxicity as an
endogenous source of lead in plasma.24 The exchange of lead
is greater during increased bone turnover such as pregnancy,
immobilization, or hyperparathyroidism.12
In patients with CRF, the urinary elimination of the
lead–EDTA complex is delayed, among patients with severe
renal failure up to 8 days, and the urinary collection is usually
extended to 72 h.21,22 Although valuable in detecting patients
with past excessive lead exposure, the sensitivity and
specificity of the EDTA diagnostic test in describing the
levels of patients below the toxic limit (o600 mg/72 h),
especially in patients with different glomerular filtration rates
(GFRs) are uncertain. Thus, the use of biomarkers to
estimate lead exposure among patients with CRF is not
sufficiently validated. PbB is a measure that could be affected
by higher bone turnover, acidosis, and inflammation, which
often is present among CRF patients. The EDTA diagnostic
test could likewise be affected by the perturbed mineral and
bone metabolism and has already been shown to differ
among patients with severe renal failure.22 Furthermore, X-
ray fluorescence has demonstrated poor sensitivity and
specificity compared with the EDTA diagnostic test among
CRF patients.18,25
GENERAL TOXICITY OF LEAD
The toxicity of lead is because of the inactivation of enzyme
systems by binding to sulfhydryl groups.3 One major effect of
lead exposure is the interference with heme biosynthesis.
Lead stimulates mitochondrial enzyme ALAD synthetase,
inhibits the cytoplasmatic enzyme ALAD dehydratase, and
interferes with intramitochondrial ferrochelatase, which
insert Fe3þ into the protoporphyrin ring. ALAD inhibition
results in the accumulation of aminolevulinic acid and zinc
protoporphyrin in blood, plasma, and urine.26 Measurement
of ALAD activity has been used as a biomarker for lead
intoxication among healthy subjects. In patients with CRF,
the ALAD activity is inhibited and therefore is more difficult
to interpret.27 Figure 1 summarizes the prevalence of
different non-renal health effects of lead at different PbB
levels.20
COMMONLY DESCRIBED RENAL EFFECTS FROM LEAD
The classical lead nephropathy exhibited at toxic levels
presents with minimal proteinuria, a benign urinary
sediment, hyperuricemia, and often hypertension.2 The
kidneys are granular and contracted. Renal biopsies show
tubular atrophy and interstitial fibrosis without cellular
infiltration.28 The glomeruli are sclerotic and the arterioles
often show intima proliferation and hyaline degeneration of
the media. In the proximal tubules, acid-fast nuclear
inclusion bodies, consisting of a lead–protein-binding com-
plex can be seen.29,30 These inclusion bodies are observed
during the initial phases of acute lead exposure, and rarely at
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Figure 1 |Blood lead in relation to reported prevalence of
non-renal health effects. Modified from Elinder et al.20
Abbreviations: ALAD, d-aminolevulinic acid; CNS, central nervous
system; ZPP, zinc protoporphyrin.
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later stages. Lead toxicity has also been shown to cause
mitochondrial swelling in the renal tubular cells and
impairment of energy production.31 In children with acute
lead poisoning, Fanconi syndrome has been seen. Figure 2
schematically presents the induction of nuclear inclusion
bodies from lead exposure. Increased urinary secretion of
N-acetyl-b-D-glucosaminidase, lysozyme, and urinary a-1-
microglobulin can be observed early among lead-exposed
individuals. In workers with PbB levels 440 mg/dl, alterations
in the secretions of the eicosanoid 6-keto-prostaglandin-F1a,
thromboxane B2, and fibronectin have been observed
together with the increased urinary secretion of brush border
antigen, intestinal alkaline phosphatase, prostaglandin-F2a,
and prostaglandin-E2.
32,33
Animal studies34–37 evaluating lead exposure and renal
function show tubular effects, nuclear inclusion bodies,
and to some extent glomerular hyperfiltration. Rats fed with
high doses of lead (mean PbB 125 mg/dl) increased their
GFR at 3 months compared with control rats, but had lower
GFR at 6 and 12 months. The kidneys had proximal tubule
inclusion bodies, interstitial fibrosis, tubular atrophy, and
focal glomerular sclerosis.35 Rats fed with lower doses of
lead (mean PbB 29 mg/dl) also presented with glomerular
hyperfiltration and increased N-acetyl-b-D-glucosaminidase
secretion after 3 months, but after 12 months the renal
biopsies showed almost no morphological changes. Chelate
treatment improved GFR both among lead-fed rats and
among control rats34,36 and reduced the morphological
changes seen after lead exposure was discontinued.37 Apart
from tubular effects of unknown clinical importance, there is
limited experimental evidence that lead (except toxic levels)
causes progressing renal failure.
RENAL EFFECTS IN ENVIRONMENTALLY EXPOSED CHILDREN
In 1929, Nye first described a high incidence of young people
with chronic nephritis in Queensland, Australia, and linked it
to the high frequency of childhood plumbism in the same
area.38 In later follow-up studies, these children treated for
lead intoxication showed a much higher age-adjusted
mortality rate caused by the chronic nephritis compared
with the general population in other areas of Australia.39
However, the relationship between childhood lead intoxica-
tion and chronic nephritis has been difficult to confirm.
A follow-up in the US of 62 children treated for plumbism in
1983 revealed no significant difference in elevation of serum
creatinine (S-Cr), proteinuria, or blood pressure after 17–23
years compared with sibling controls.40 Yet another follow-up
study of children treated for lead intoxication during
1932–1945 showed no significant difference in S-Cr com-
pared with controls, but the exposed subjects had higher
creatinine clearance and higher blood pressure.41 Two recent
studies on adolescents show the same positive cross-sectional
relationship between PbB and cystatin C or S-Cr observed
among adults.42,43 Even though it has been difficult to
establish that childhood lead intoxication causes renal failure,
there is reason to believe that lead exposure may be more
hazardous to children compared with adults.
OCCUPATIONAL LEAD EXPOSURE AND CRF
PbB levels, although higher than in the general population,
have declined also among lead workers over the past decades,
probably because of the better general work environment and
direct preventive incentives to reduce lead exposure.44,45
Occupational studies investigating lead exposure have
been cross-sectional with a few exceptions. In Table 1, we
have compiled and commented on all cross-sectional studies
available to us with data on GFR (or estimated GFR) from
occupationally exposed individuals since 1985, totaling 19
different reports. The majority of the studies have used
imprecise measures of renal function, such as S-Cr, blood
urea nitrogen, or creatinine clearance. In spite of all that has
been reported on the effects from acute or ongoing excessive
exposure, there are only a few of the studies presented in
Table 1 in which the GFR is significantly reduced.46,47 The
approximate frequency of CRF (GFR o60 ml/min) from
these observations is 1.5%. This is almost identical to the
population prevalence of stage 3 chronic kidney disease
(1.4%) among 40- to 59-year-old subjects.48 Longitudinal
Figure 2 |Renal proximal tubular cell. The left side of the cell
shows invagination of nuclear membrane around the inclusion
body, mitochondrial swelling, and an aggregate of fibrillary
lead–protein complex that forms a nuclear inclusion body.
The right side shows a normal tubular cell.
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Table 1 | Summary of cross-sectional studies since 1985 on occupationally exposed lead workers with individual measurements
of blood lead, serum creatinine, and/or other measures of glomerular filtration rate (GFR)
Year of
publication Reference Description
Control group and
results Renal function marker Comment
1985 Bennett70 Case report of a worker with
reduced GFR and a history
of long-term occupational
lead exposure. PbB 59, EDTA
test 3266mg/24 h. Duration
of exposure, 25 years
No control group. Renal
biopsy revealed non-
specific tubulointerstitial
disease and
nephrosclerosis
eGFR 18 ml/min per 1.73 m2,
CrCl 23–28 min/1.73 m2
Renal damage may well
have been caused by other
types of exposures and/or
conditions
1986 Greenberg et al.71 Cadmium- and lead-
exposed workers. Mean PbB
32, range 9–60, EDTA test
elevated in 22 of the
workers, n=38
No control group. All
CrCl measurements in
the normal range
Mean CrCl 130 ml/min
per 1.73 m2
No evidence of reduced GFR
in lead-exposed workers
1986 Pollock and
Ibels72
Case reports from six lead-
exposed and -intoxicated
men. Mean PbB 70, range
48–87, EDTA test
698–1457mg/72 h. Duration
of exposure, 6–28 years, n=6
No control group.
Symptoms of lead
toxicity from the nervous
system
Mean CrCl was 97 ml/min,
range 49–127, the lowest
value for a man with a
nephrotic syndrome
One individual with CRF of
uncertain cause. Renal
biopsies from two men
showed non-specific
changes and no inclusion
bodies
1987 Pinto de Almeida
et al.46
Lead-exposed primary lead
smelters. Mean PbB 64,
range 48–80, n=52. Duration
of exposure, 7–23 years
Control group, n=44.
Marginally (10%) but
significantly higher S-Cr
among exposed
compared with control
groups
Mean S-Cr 108mmol/l, s.d.
30. Mean eGFR 68 ml/min
per 1.73 m2, mean CrCl
among exposed 119 ml/min
17 Workers with eGFR o60.
Slightly higher S-Cr among
the exposed group may
have other causes than lead
1987 Verschoor et al.73 Lead-exposed workers.
Mean PbB 47, range 21–97,
duration of exposure,o2 to
410 years, n=153
Control group, n=126.
No difference in S-Cr
between exposed and
control groups
Mean S-Cr 85mmol/l, s.d. 14.
No difference between
exposed and controls. Mean
eGFR 90 ml/min per 1.73 m2
No evidence of reduced GFR
in lead-exposed workers,
and no difference compared
with control group
1987 De Kort et al.74 Lead-exposed workers.
Mean PbB 47, range 44–51,
mean duration of exposure,
12.5 years, n=53
Control group, n=52. No
difference in S-Cr
between exposed and
control groups
S-Cr average 87mmol/l, s.d.
12. No difference between
exposed and controls. Mean
eGFR 90 ml/min per 1.73 m2
No evidence of reduced GFR
in lead-exposed workers,
and no difference compared
with control group
1987 Ong et al.75 Lead-exposed workers at
two sites. PbB 42 and 32
(men and women), range
3–80, n=209
No control group. S-Cr
and CrCl measurements
in the normal range.
Significant positive
correlation between
PbB, S-Cr, and CrCl
Mean CrCl (exposed men)
121 (s.d. 41) and 118 ml/min
(exposed women)
No evidence of reduced GFR
in lead-exposed workers.
Significant correlations
between PbB, S-Cr, and CrCl
possibly confounded by age
and gender
1987 Maranelli and
Apostoli76
Lead-exposed workers
admitted to a clinic with
diagnosis ‘lead poisoning’.
Mean PbB 72, range 50–128,
n=60
No difference in S-Cr
between exposed and
control groups. No
difference in S-Cr
between workers with
lower and those with the
higher urinary excretion
of lead after EDTA test
Mean CrCl in exposed
workers was 95 ml/min,
s.d. 29.
No evidence of reduced GFR
in lead-exposed workers,
and no difference compared
with control group
1990 Omae et al.77 Lead-exposed workers.
Mean PbB 37, range 6–73,
duration of exposure, 0.1–26
years, n=165
No control group. CrCl
measurements in the
normal range, no
difference between high-
and low-PbB groups
Mean CrCl in six different
PbB groups 99–110 ml/min,
range 75–150
No evidence of reduced GFR
in lead-exposed workers
1992 Gennart et al.78 Lead-exposed workers.
Mean PbB 51, range 40–75.
Duration of exposure, 1–28
years, n=98
Control group, n=85.
No difference in S-Cr
between exposed and
control groups
Mean S-Cr 95 mmol/l, mean
eGFR 107 ml/min per
1.73 m2, range 49–176
No difference in S-Cr and
CrCl compared with control
group
1992 Gerhardsson
et al.79
Lead-exposed workers. Mean
PbB 32, range 3–47, mean
duration of exposure, 14 and
33 years among active and
retired workers, n=100
Control group, n=41.
No difference in P-Cr
between exposed and
control groups
Mean S-Cr 90 mmol/l, range
63–117. Mean eGFR 88 ml/
min per 1.73 m2 (65–125) for
active and 74 (62–117) for
retired workers
No evidence for CRF among
lead-exposed workers. No
difference compared with
control group
1993 Ca´rdenas et al.32 Lead-smelter workers. Mean
PbB 48, range 36–65, mean
duration of exposure, 14
years, n=41
Control group, n=41.
No difference in S-Cr
between exposed and
control group
Mean S-Cr 90 mmol/l (s.d.
10), mean eGFR 87 ml/
min per 1.73 m2
No evidence of reduced GFR
in lead-exposed workers,
and no difference compared
with control group
Table 1 Continued on following page
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studies provide no further evidence of lead causing CRF. The
largest longitudinal study on 537 lead workers followed for
42.1 years showed no general effect of PbB (mean baseline
31.3 mg/dl) on creatinine clearance.45 Mean creatinine
clearance increased during the study period. In another
longitudinal study of 30 lead workers followed for 410 years,
higher PbB at baseline was associated with a subsequent
decrease in S-Cr, suggesting hyperfiltration.44 In our own
recently published follow-up study of patients with severe
CRF, we did not find a more rapid decline in the estimated
GFR during 5–7 years among patients occupationally exposed
to lead compared with those non-exposed. Neither was renal
survival significantly decreased (hazard ratio 0.92 (95%
confidence interval 0.7–1.2) for ever exposed participants
compared with never-exposed).49
ENVIRONMENTALLY EXPOSED POPULATIONS AND
INDICATORS OF RENAL EFFECTS
Most of the general population studies are also cross-
sectional. The majority of the studies with renal function
outcomes use S-Cr or creatinine clearance,5,6,14,50–52 whereas
some studies used cystatin C.42,53,54 The mean PbB levels
ranged between 2.2 and 43.5 mg/dl. Although most of these
studies showed an association between higher PbB and lower
creatinine clearance or estimated GFR,5,14,42,50,51,53 two
studies (of which one was on children) instead presented
an inverse correlation,52,54 one study found an association
only among the hypertensives,6 and one lacked any associa-
tion.55 In the largest study from the United States, people in
the highest quartile of PbB (X2.47 mg/dl) were 2.72 times
more likely to have chronic kidney disease stage 3 or less
based on estimated GFR (four-variable Modification of Diet
in Renal Disease 2000) compared with the lowest quartile
(o1.06 mg/dl).14
There are two longitudinal studies published of the
general population, and they used the same cohort of
men.56,57 In one of them, there was a higher age-related
increase in S-Cr for subjects with higher time-weighted
average PbB levels. In the other study, higher tibia lead
predicted a higher increase in S-Cr among patients with
Table 1 | Continued
Year of
publication Reference Description
Control group and
results Renal function marker Comment
1994 Roels et al.68 Lead workers. Mean PbB 43,
range 26–68, mean duration
of exposure, 18 years, n=76
Control group, n=68.
No difference in CrCl
between exposed and
control group. PbB
related to increase
in S-Cr
eGFR 69–132 ml/min per
1.73 m2. Mean CrCl 121 ml/
min per 1.73 m2
No evidence of reduced GFR
1995 Kumar and
Krishnaswamy80
Lead-exposed auto
mechanic workers. Mean not
given, PbB range 24–62,
n=22
Control group, n=27.
Lead toxicity symptoms
in 36% of the exposed
group. No difference in
P-Cr between exposed
and control groups
Mean eGFR 87 ml/min per
1.73 m2. Mean CrCl (4 h)
58 ml/min, s.d. 6
GFR o60 ml/min in a few
workers, but no difference
compared with controls
1998 Ehrlich et al.47 Lead battery factory
workers. Mean PbB 53,
range 23–110. Mean
duration of exposure, 12
years (0.5–44 years), n=382
No control group.
Correlations between
PbB, historical PbB and
S-Cr, and urate
Mean S-Cr 100mmol/l, s.d.
16. Mean eGFR 87 ml/min
per 1.73 m2. Range 43–159
A few workers with GFR
o60 ml/min in highest
exposure group (toxic
levels)
2001 Lim et al.81 Lead-exposed PVC plastic
workers. PbB range
8–45, n=55
No control group.
Normal values of CrCl
Mean CrCl 113–126 ml/min
per 1.73 m2, s.d. 14.2
No evidence of reduced GFR
in lead-exposed workers
2002 Wang et al.82 Lead battery factory
workers. Mean PbB 68 and
49 for men and women.
Duration of exposure, 0.2
to 410 years, n=229
No control group.
Normal range of eGFR
Mean eGFR 80 ml/min per
1.73 m2 in both low and
high PbB group
No evidence of CRF among
lead-exposed workers
2005 Weaver et al.83 Lead-exposed workers.
Mean PbB 32 range 4–86,
n=803. Mean duration,
8.2 years
No control group.
Almost no abnormal
CrCl. Statistical
associations between
PbB and uric acid among
elderly workers
Mean estimated CrCl 95 ml/
min, range 41–184
No evidence of reduced GFR
in lead-exposed workers
2007 Orisakwe et al.84 Lead-exposed paint factory
workers. PbB 39 (s.d. 4),
duration of exposure,
0.5–20 years, n=25
Controls n=25. No
difference in S-Cr
compared with control
groups
Mean eGFR 84 ml/min
per 1.73 m2
No evidence of reduced GFR
and no difference compared
with controls
Abbreviations: BUN, blood urea nitrogen; CrCl, creatinine clearance; CRF, chronic renal failure; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate;
n, number; PbB, blood lead; S-Cr, serum creatinine; S/P, serum or plasma.
PbB in mg/dl. To convert to mmol/l, multiply by 20.72. S/P-creatinine (S-Cr) in mmol/l. To convert to mg/dl, divide by 88.4. eGFR is calculated from the four-variable
Modification of Diet in Renal Disease equation.
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diabetes (n¼ 26) or hypertension. Our interpretation is that
although cross-sectional evidence for a link between PbB and
different estimations of GFR exists, the evidence is hypothesis
generating rather than indicative of a causative association.
The cross-sectional evidence has been difficult to replicate in
the few longitudinal studies that have been published.
LEAD EXPOSURE AND CRF OUTCOMES
Only four case–control studies investigating lead exposure
and its association with CRF are published. One study
measuring lead by the expert rating method58 found that the
odds ratio (OR) for CRF associated with lead exposure was
2.1 (95% confidence interval 1.2–4.4).59 Another similar
case–control study found no such association.60 In one pilot
study, 55 patients with end-stage renal disease had signifi-
cantly higher PbB compared with 53 age and sex-matched
controls,61 whereas mean tibia lead did not differ signifi-
cantly. The OR for end-stage renal disease associated with
tibia leadX20 mg/g was 1.6 (95% confidence interval 0.6–4.4)
and thus showed a non-significant positive association. In
our recently published study, the OR associated with lead
exposure was 0.97 (95% confidence interval 0.68–1.38)
compared with non-exposure among 926 patients with
incident CRF compared with 998 population controls.49
Thus, only one case–control study, using prevalent patients,
demonstrated a significant association, whereas the only
study with incident CRF found no association.
In a series of investigations, Lin and colleagues62–65 present
data in which a higher lead burden measured by the EDTA
diagnostic test is associated with a more rapid deterioration
rate in CRF patients of different etiologies. Their environ-
mentally exposed patients in Taiwan had PbB comparable
with the general populations in Europe and the United
States.66 The patients treated with repeated chelate therapy
progressed slower than those who did not receive any
treatment.64 Confounding factors, such as acidosis, inflam-
mation, and hyperparathyroidism, were not measured, and
patients were followed only through S-Cr. Given the limited
knowledge and validation of the EDTA test among CRF
patients, these studies are interesting, but, as long as
additional confounding factors and GFR are not measured
more thoroughly, they cannot be regarded as evidence of a
causative effect.
DISCUSSION
There is good anecdotal evidence that lead nephropathy may
develop after high and prolonged exposure. In the occupa-
tional studies, in which individuals had been exposed to lead
at high levels for many years giving rise to PbB 460 mg/dl or
an EDTA test diagnostic test 4600 mg/24 h, there is possibly a
risk of developing acute lead nephropathy with typical
morphological findings in the kidney, hypertension, and
often elevated plasma uric acid. However, data indicating that
lead causes CRF and the development of end-stage renal
disease are scarce. In Europe, the number of individuals with
lead nephropathy as a reported cause of ESRD is indeed very
low; 7 reported cases out of 143,733 patients with ESRD
(Kramer A. ERA-EDTA Registry. Personal communication,
2008). Even considering the shortcomings of register data,
this may be indicative of the magnitude of the association.
Likewise, the possible effect from lead exposure on the
progression of kidney disease is unclear. The very few
longitudinal studies on exposed workers have not supported
a deteriorating renal function except in some risk popula-
tions of patients with diabetes or hypertension,6,57 but rather
increased clearances at low exposure levels indicating
hyperfiltration.44,45,67 Whether this hyperfiltrating state can
damage the kidneys in the long term is uncertain. Animal
studies have also failed to demonstrate reliable evidence for a
long-term effect on the glomerular function when lead levels
are below toxic.
In occupational studies, the ‘healthy worker effect’
(workers are generally healthier compared with the general
population, which gives occupational cohorts survival
advantages) is always a matter. Even though workers in the
lead studies were almost never compared with the general
population, the healthy worker effect may create a selection
bias problem if workers with early signs of renal function loss
were removed from the work force. Because of the slowly
progressive nature of kidney disease and the fact that CRF
usually is symptomatic only at the very latest stages (GFR
o20 ml/min per 1.73 m2), we think that it is unlikely that
these selection problems affected the results to any large
extent, unless workers were screened for kidney failure on a
regular basis. Cross-sectional studies have previously been
able to establish sufficient evidence for a renal damage in
occupational cohorts studying other exposures, for example
cadmium.68 In prospective longitudinal studies, the healthy
worker effect is less important if not loss to follow-up is
significant.
In the studies linking low-level environmental lead
exposure to renal disease in the general population there
are positive associations between PbB and S-Cr, and to some
degree cystatin C. The associations have been shown
repeatedly and for populations both in Europe and the
United States.5,14 The question is, however, whether there is
causality. The association between PbB and cystatin C/serum
creatinine in the general population is present also within a
normal range of estimated GFR and almost at the detection
limit of PbB. This may be indicative of the fact that factors
other than glomerular filtration (confounders) are involved
in the cross-sectional relationship. In addition, patients with
severe CRF do not have increased bone lead levels compared
with the general population.69 One may speculate that PbB is
elevated in CRF patients as a consequence of altered
bioavailability, perhaps caused by the increased prevalence
of acidosis, malnutrition, inflammation, disturbed bone and
mineral metabolism, and hyperparathyroidism. Moreover,
these factors can increase the decline in GFR, thereby
introducing bias also in prospective observational studies.
Genetic differences may contribute to the differences in the
susceptibility of lead among the ethnic groups studied. It is
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likewise important to note that anemia, capable of influen-
cing PbB estimates, is often present in patients with renal
disease.44 The role of ALAD inhibition present among CRF
patients, and its relationship with PbB and lead toxicity, is
also unclear. It may be true that PbB really reflects an
increased risk of hypertension, kidney disease, and cardio-
vascular mortality, but there is a great possibility that the
results are driven by confounding factors and reverse
causation.
To confirm the old ‘fact’ that lead exposure causes
deterioration of the GFR, CRF, and eventually end-stage
renal disease, additional well-controlled longitudinal studies
with adequate exposure and effect variables are needed. It is
necessary to better validate the biomarkers of lead exposure
among patients with renal failure, and more precise
measurements of the GFR than p-creatinine are essential.
Additional experimental evidence is required to establish a
causative platform. Until these measures are undertaken, the
relationship between CRF and lead exposure below the toxic
level must be considered to be merely associative.
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